Juvmo (tavapadon)

Name: Juvmo (tavapadon) in Parkinson's disease: Ongoing post-approval monitoring
Published: 2026-09-27T21:44:59-04:00

Parkinson's disease

Also known as CVL-751

Manufacturer: AbbVie
Regulatory submission: NDA submitted September 2025
Launch: Expected by Citi analysts in the third quarter of 2026
Last updated: October 1, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Ongoing post-approval monitoring

2 evidence topics · 3 sources

Long-term open-label extension trial

“An open-label extension study (TEMPO-4) is ongoing to assess the long-term safety and efficacy of tavapadon through 58 weeks of treatment. TEMPO-4 enrolled patients who completed participation in TEMPO-1 through 3, as well as patients on stable doses of levodopa who had not been in prior TEMPO trials.” (opens the source at this quote in a new tab)

“Open-label Trial in Parkinson's Disease (PD)” (opens the source at this quote in a new tab)

Adverse reaction reporting

“To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.” (opens the prescribing information at this quote)